Dosing method may eliminate genetic test need
Giving irinotecan (Camptosar, Pfizer) at low doses for several days may eliminate the need for the genetic test that determines whether a patient carries a variation in the UGT1A1 gene, putting one at risk for increased toxicity.
Giving irinotecan (Camptosar, Pfizer) at low doses for several days may eliminate the need for the genetic test that determines whether a patient carries a variation in the UGT1A1 gene, putting one at risk for increased toxicity. Researchers at St. Jude Children's Research Hospital have found that when given the drug in small doses for two weeks instead of the standard single large dose once a month, children can begin treatment with irinotecan immediately and not have to delay treatment to perform the genetic test. A report of this study was published in the June 20 issue of the Journal of Clinical Oncology.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
How Mark Cuban Cost Plus Drug Company Is Approaching Drug Pricing Transparency
October 14th 2024Erin Albert, vice president of pharmacy relations and chief privacy officer at Mark Cuban Cost Plus Drug Company, PBC, discussed drug pricing and what her company is doing to revolutionize transparency.
